Prausova Jana - Researcher Profile | RDL Research Database

Publications

2 shown

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness , Kevin J. Harrington , Richard Greil +97 more

2019 The Lancet 2928 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the add...

2020 The Lancet 1658 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 4,586

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.